Fig. 7

CARMN inhibits TNBC cell proliferation and promotes cisplatin sensitivity through producing miR143-3p which can combine and down regulate MCM5. A Efficiency of CARMN exon5 overexpression in TNBC cells. B Change of miR143-3p expression in CARMN exon5 overexpressed cells. C Change of MCM5 expression in CARMN exon5 overexpressed cells. D Influence of DROSHA and DICER1 suppression on miR143-3p level. E Effect of DROSHA and DICER1 suppression on CARMN expression (left) and CARMN exon5 (right). F Predicted binding site of miR143-3p and MCM5 (left). Luciferase reporter assay indicating binding ability of miR143-3p and 3’UTR of MCM5 in two predicted area (right). G Effect of miR143-3p inhibition on expression of MCM5 mRNA (left) and MCM5 protein (right) level in TNBC cells with or without CARMN overexpression. H Efficiency of miR143-3p inhibitor in TNBC cells with or without CARMN exon5 overexpression. I Effect of miR143-3p inhibition on expression of MCM5 mRNA (left) and MCM5 protein (right) level in TNBC cells with or without CARMN exon5 overexpression. cDDP: cisplatin. Error bars represent means ± SD, *P < 0.05, **P < 0.01, ***P < 0.001